Patient factors associated with frequent clotting of dialysers during haemodiafiltration in critically ill patients: A post hoc analysis of a randomised controlled study

Anaesthesia and Intensive Care

Volumn 42, Issue 1, 2014, Pages 59-64

  Ho, K M ^a,b   Morgan, D J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Acute kidney injury; Dialysis; Predictors; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; CLOPIDOGREL; HEPARIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BLOOD TRANSFUSION; BODY MASS; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIALYSIS CATHETER; FEMALE; FOLLOW UP; HEART RIGHT ATRIUM; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUPERIOR CAVA VEIN; THROMBOCYTE COUNT;

EID: 84893843634     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1404200111     Document Type: Article

References (17)

1. Morgan DJ, Ho KM. A comparison of nonoliguric and oliguric severe acute kidney injury according to the risk injury failure loss end-stage (RIFLE) criteria. Nephron Clin Pract 2010; 115:c59-65.
2. RENAL Study Investigators. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. Crit Care Resusc 2008; 10:225-230.
3. Morgan D, Ho K, Murray C, Davies H, Louw J. A randomized triaLof catheters of different lengths to achieve right atrium versus superior vena cava placement for continuous renal replacement therapy. Am J Kidney Dis 2012; 60:272-279.
4. Duff OC, Ho KM, Maybury SM. In vitro thrombotic tendency of reactive thrombocytosis in critically ill Lpatients: a prospective case-control study. Anaesth Intensive Care 2012; 40:472-478.
5. Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11:218.
6. Zhang Z, Ni H, Lu B. Variables associated with circuit life span in critically ill Lpatients undergoing continuous renal replacement therapy: a prospective observational study. ASAIO J 2012; 58:46-50.
7. Ho KM, Tan JA. Can the presence of significant coagulopathy be useful to exclude symptomatic acute pulmonary embolism? Anaesth Intensive Care 2013; 41:322-327.
8. Ho KM, Chavan S. Prevalence of thrombocytosis in critically ill Lpatients and its association with symptomatic acute pulmonary embolism. A multicentre registry study. Thromb Haemost 2013; 109:272-279.
9. Ho KM, Burrell M, Rao S, Baker R. Incidence and risk factors for fataLpulmonary embolism after major trauma: a nested cohort study. Br J Anaesth 2010; 105:596-602.
10. Harrell FE Jr. Regression Modeling Strategies. New York: Springer; 2001.
11. Ho KM, Knuiman M, Finn J, Webb SA. Estimating long-term survivaLof critically ill Lpatients: the PREDICT model. PLoS One 2008; 3:e3226.
12. Davies H, Morgan D, Leslie G. A regionaLcitrate anticoagulation protocoLfor pre-dilutionaLCVVHDf: the 'Modified Alabama Protocol'. Aust Crit Care 2008; 21:154-165.
13. Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D et al. RegionaLcitrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother 2009; 43:1419-1425.
14. Morgan DJ, Ho KM. Profound hypocalcaemia in a patient being anticoagulated with citrate for continuous renal replacement therapy. Anaesthesia 2009; 64:1363-1366.
15. Ho KM, Bertenshaw C, Same S, Schneider M, Williams KA, Godsell T et al. Differential associations between body mass index and outcomes after elective adult cardiac surgery: a linked data cohort study. Anaesth Intensive Care 2013; 41:573-583.
16. Stein PD, Goldman J. Obesity and thromboembolic disease. Clin Chest Med 2009; 30:489-493.
17. Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost 2012; 10:1768-1774.